Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen - Archive ouverte HAL Access content directly
Journal Articles Clinical Infectious Diseases Year : 2018

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

1 CPTP - Centre de Physiopathologie Toulouse Purpan
2 UT3 - Université Toulouse III - Paul Sabatier
3 Laboratoire Virologie [CHU Toulouse]
4 Hôpital Paul Brousse
5 CHU Bordeaux [Bordeaux]
6 Laboratoire de Virologie [Rennes] = Virology [Rennes]
7 HCL - Hospices Civils de Lyon
8 CHU Saint-Antoine [AP-HP]
9 CHU Hôtel-Dieu - Centre Hospitalier Universiatire Hôtel-Dieu de Nantes
10 CHU Tenon [AP-HP]
11 Centre Hospitalier Universitaire de Rouen
12 CHU de Lille - Centre Hospitalier Universitaire de Lille
13 CHU Poitiers - Centre hospitalier universitaire de Poitiers
14 Hôpital Henri Mondor
15 CHU Pitié-Salpêtrière [AP-HP]
16 IAME (UMR_S_1137 / U1137) - Infection, Anti-microbiens, Modélisation, Evolution
17 INSERM UMR-S 606, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, PRES Sorbonne Paris-Cité, and Université Paris Denis Diderot,
18 Laboratoire de Virologie [AP-HP Hôpital Bichat-Claude-Bernard]
19 CHU Nancy - Centre Hospitalier Universitaire de Nancy
20 CHU Clermont-Ferrand
21 Service de Virologie [CHU Caen]
22 CHU Angers - Centre Hospitalier Universitaire d'Angers
23 CeRéMAIA - Hôpital André Mignot - Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses [CH Versailles]
24 CHU de Grenoble - Centre hospitalier universitaire de Grenoble
25 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours
26 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
27 Hôpital Necker
28 Centre Hospitalier Universitaire d'Amiens
29 INSERM - Institut National de la Santé et de la Recherche Médicale
30 AP-HP, Hôpital Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique et Maladies Infectieuses 94000 Créteil, France
31 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Florence Nicot
  • Function : Author
  • PersonId : 906169
Laurence Morand-Joubert
  • Function : Author
  • PersonId : 972692
Corinne Amiel
  • Function : Author
Magali Bouvier-Alias
  • Function : Author
  • PersonId : 881464
Sidonie Lambert-Niclot
  • Function : Author
  • PersonId : 916115
Vincent Calvez
  • Function : Author
  • PersonId : 916123


Background. Minority resistant variants of human immunodeficiency virus type 1 (HIV-1) could influence the virological response to treatment based on nonnucleoside reverse transcriptase inhibitors (NNRTIs). Data on minority rilpivirine-resistant variants are scarce. This study used next-generation sequencing (NGS) to identify patients harboring minority resistant variants to nucleos(t) ide reverse transcriptase inhibitors and NNRTIs and to assess their influence on the virological response (VR). Methods. All the subjects, 541 HIV-1-infected patients started a first-line regimen containing rilpivirine. VR was defined as a HIV-1 RNA load <50 copies/mL at month 6 with continued suppression at month 12. NGS was performed at baseline (retrospectively) on the 454 GS-FLX platform (Roche). Results. NGS revealed resistance-associated mutations accounting for 1% to <5% of variants in 17.2% of samples, for 5%-20% in 5.7% of samples, and for >20% in 29% of samples. We identified 43 (8.8%) and 36 (7.4%) patients who harbored rilpivirine-resistant variants with a 1% sensitivity threshold according to the French National Agency for Research on AIDS and Viral Hepatitis and Stanford algorithms, respectively. The VR was 96.9% at month 12. Detection of minority rilpivirine resistant variants was not associated with virological failure (VF). Multivariate analysis indicated that VF at month 12 was associated with a CD4 count <250 cells/mu L at baseline, a slower decrease in viral load at month 3, and rilpivirine resistance at baseline using the Stanford algorithm with a 20% threshold. Conclusions. Minority resistant variants had no impact on the VR of treatment-naive patients to a rilpivirine-based regimen.

Dates and versions

hal-01899957 , version 1 (20-10-2018)



Stéphanie Raymond, Florence Nicot, Coralie Pallier, Pantxika Bellecave, Anne Maillard, et al.. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. Clinical Infectious Diseases, 2018, 66 (10), pp.1588 - 1594. ⟨10.1093/cid/cix1070⟩. ⟨hal-01899957⟩
572 View
0 Download



Gmail Facebook X LinkedIn More